INS and type 2 diabetes mellitus: In both the T2D-B and T2D-MDI treatment cohorts, isCGM users with suboptimal glycaemic management and baseline HbA1c ≥58.5 mmol/mol (≥7.5%) were compared with HbA1c-matched BGM control participants with type 2 diabetes on basal insulin and multiple daily injection regimens (Fig. 1).